Discontinuation of Additional Risk Minimisation Measure Tools Implemented at Authorisation for Centrally Authorised Medicinal Products in the EU

Additional risk minimisation measure (aRMM) tools should be periodically reassessed to determine whether they remain effective and necessary. To evaluate discontinuations of aRMM tools for medicinal products in the European Union (EU). We combined a retrospective cohort study with qualitative document analysis of regulatory decisions. Medicinal products centrally authorised with aRMM tools in the EU between July 2012 and December 2021 were included and followed until 31 December 2025. Discontinued aRMM tools were identified through publicly available regulatory documents, and discontinuation rationales were extracted from non-public assessment reports. Kaplan–Meier analyses estimated discontinuation probabilities at product and tool level, and thematic analysis was used to characterise discontinuation rationales. During follow-up, at least one aRMM tool was discontinued for 22/132 products. The probability of discontinuing at least one aRMM tool within five years after authorisation was 5.0% (95% CI 1.0–8.8; n at risk = 104) and 29.2% (95% CI 16.6–39.9; n at risk = 30) within ten years. 32/306 unique aRMM tools were discontinued, including predominantly educational tools for healthcare professionals ( n = 22). The probability of aRMM tool discontinuation within five years after authorisation was 2.5% (95% CI 0.7–4.4; n at risk = 242), increasing to 20.5% (95% CI 13.2–27.1; n at risk = 76) within ten years. Discontinuation decisions were based on multifactorial rationales, related to implementation of aRMM tools, risk-related appropriateness of aRMM tools, and broader regulatory considerations (e.g. consistency across products). Post-authorisation discontinuation of aRMM tools occurred in about one-quarter of products within ten years after authorisation. Decisions were multifactorial, with variation in the evidence considered and limited relevance of dedicated effectiveness studies. Clearer guidance, including discontinuation criteria, may improve consistency in decision-making.

Authors

Institutions

Publication Details

Journal
Drug Safety
Published
2026-11-15
DOI
https://doi.org/10.1007/s40264-026-01749-4
Primary Topic
Pharmacovigilance and Adverse Drug Reactions
Type
article
Field-Weighted Citation Impact
0.00
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
NOV
article

Discontinuation of Additional Risk Minimisation Measure Tools Implemented at Authorisation for Centrally Authorised Medicinal Products in the EU

Sharon C. M. Essink, Valerie Strassmann, Thomas Goedecke, Marie L. De Bruin et al.
Drug Safety
Pharmacovigilance and Adverse Drug Reactions
article

Discontinuation of Additional Risk Minimisation Measure Tools Implemented at Authorisation for Centrally Authorised Medicinal Products in the EU

Sharon C. M. Essink, Valerie Strassmann, Thomas Goedecke, Marie L. De Bruin, Sabine M. J. M. Straus, Helga Gardarsdóttir, Inge M. Zomerdijk
article en

Abstract

Additional risk minimisation measure (aRMM) tools should be periodically reassessed to determine whether they remain effective and necessary. To evaluate discontinuations of aRMM tools for medicinal products in the European Union (EU). We combined a retrospective cohort study with qualitative document analysis of regulatory decisions. Medicinal products centrally authorised with aRMM tools in the EU between July 2012 and December 2021 were included and followed until 31 December 2025. Discontinued aRMM tools were identified through publicly available regulatory documents, and discontinuation rationales were extracted from non-public assessment reports. Kaplan–Meier analyses estimated discontinuation probabilities at product and tool level, and thematic analysis was used to characterise discontinuation rationales. During follow-up, at least one aRMM tool was discontinued for 22/132 products. The probability of discontinuing at least one aRMM tool within five years after authorisation was 5.0% (95% CI 1.0–8.8; n at risk = 104) and 29.2% (95% CI 16.6–39.9; n at risk = 30) within ten years. 32/306 unique aRMM tools were discontinued, including predominantly educational tools for healthcare professionals ( n = 22). The probability of aRMM tool discontinuation within five years after authorisation was 2.5% (95% CI 0.7–4.4; n at risk = 242), increasing to 20.5% (95% CI 13.2–27.1; n at risk = 76) within ten years. Discontinuation decisions were based on multifactorial rationales, related to implementation of aRMM tools, risk-related appropriateness of aRMM tools, and broader regulatory considerations (e.g. consistency across products). Post-authorisation discontinuation of aRMM tools occurred in about one-quarter of products within ten years after authorisation. Decisions were multifactorial, with variation in the evidence considered and limited relevance of dedicated effectiveness studies. Clearer guidance, including discontinuation criteria, may improve consistency in decision-making.

Drug Safety
European Medicines Agency (NL), University of Iceland (IS), Utrecht University (NL), University Medical Center Utrecht (NL), Medicines Evaluation Board (NL)
Pharmacovigilance and Adverse Drug Reactions
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.

Laika access coming soon